

Clinical Criteria

Subject: Reblozyl (luspatercept)
Document #: ING-CC-0156 Publish Date: 03/23/2020
Status: New Last Review Date: 02/21/2020

Table of Contents

[Overview](#) [Coding](#) [References](#)
[Clinical criteria](#) [Document history](#)

Overview

This document addresses the use of Reblozyl (luspatercept). Reblozyl is an erythroid maturation agent used to treat anemia in adults with beta thalassemia who require regular red blood cell transfusions.

Beta thalassemia is an inherited blood disorder caused by mutations in the beta-globin (*HBB*) gene. These mutations result in defective red blood cells (RBC) that have little or no hemoglobin, the iron-containing protein that is responsible for oxygen transport. People who inherit just one *HBB* gene mutation (thalassemia minor or thalassemia trait) are usually asymptomatic. People who inherit two defective genes develop beta thalassemia with moderate anemia that can be managed with intermittent RBC transfusions (beta thalassemia intermedia) or severe anemia that is transfusion-dependent (beta thalassemia major, also called Cooley's anemia). Hemoglobin E beta thalassemia (E/β-thalassemia) and hemoglobin S beta thalassemia (S/β-thalassemia, also known as sickle beta thalassemia) are related disorders that occur when beta thalassemia is combined with another gene mutation or abnormality.

One of the risks that occurs with multiple blood transfusion is iron overload. Therefore, many of these patients also require life-long iron chelation therapy to manage this complication.

Reblozyl is the first drug to receive FDA approval to treat anemia in adults with transfusion-dependent beta thalassemia. It is also the first erythroid maturation agent to receive FDA approval. While Reblozyl may reduce the transfusion burden and, therefore, lower the need for iron chelation therapy, it does not completely eliminate the need for RBC transfusions. Per labeling, Reblozyl is to be administered by a healthcare professional as a subcutaneous injection. At this time, Reblozyl is not recommended for pediatric use due to findings from toxicity studies in juvenile animals.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Reblozyl (luspatercept)

Requests for Reblozyl (luspatercept) may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; AND
- II. Individual has a diagnosis of beta thalassemia or hemoglobin E beta (E/β)-thalassemia; AND
- III. Individual required regular red blood cell transfusions at initiation, defined as *both* of the following (NCT02604433):
 - A. Individual received six to twenty (6-20) RBC units in the last 24 weeks; AND
 - B. Individual had no transfusion-free period greater than 35 days in the last 24 weeks; AND
- IV. Individual has a baseline hemoglobin (Hgb) level less than or equal to 11 g/dL.

Reblozyl (luspatercept) may not be approved for the following:

- I. Individual has a diagnosis of sickle beta thalassemia (S/β-thalassemia); OR

Formatted: Underline
Formatted: Font: Not Bold, Underline

Formatted: Underline
Formatted: Underline

Formatted: Font: Not Bold, Underline
Formatted: Underline

Formatted
Formatted: Underline

Formatted
Formatted: Underline

Formatted
Formatted: Underline

Formatted
Formatted: Underline

Formatted: Underline
Formatted: Underline
Formatted: Underline

Formatted: Font: Not Bold, Underline
Formatted: Underline

Formatted: Font: Not Bold, Underline
Formatted: Underline

Formatted: Font: Not Bold, Underline
Formatted: Underline

Formatted
Formatted

Formatted
Formatted

Formatted
Formatted

- II. Individual has a diagnosis of alpha (α)-thalassemia; OR
- III. Individual has a platelet count greater than $1000 \times 10^9/L$; OR
- IV. History of deep vein thrombosis (DVT) or stroke within the last 24 weeks; OR
- V. Use beyond 9 weeks of treatment (i.e., administration of 3 doses) in the absence of response (response defined as decrease in transfusion burden from baseline) at maximum dose level (i.e., 1.25 mg/kg every 3 weeks); OR
- VI. When the above criteria are not met and for all other indications.

Quantity Limits

Reblozyl (luspatercept) Quantity Limits

Drug	Limit
Reblozyl 25 mg, 75 mg vial	1.25 mg/kg per 3 weeks

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

CPT

- 96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

HCPCS

- C9399 Unclassified drugs or biologicals (when specified as luspatercept-aamt [REBLOZYL]) (Hospital outpatient use only)
- J3490 Unclassified drugs (when specified as luspatercept-aamt [REBLOZYL])
- J3590 Unclassified Biologics (when specified as luspatercept-aamt [REBLOZYL])

ICD-10 Diagnosis

- D56.1 Beta Thalassemia
- D56.5 Hemoglobin E-Beta thalassemia

Document History

New: 02/21/2020

Document History:

- 02/21/2020 – Annual Review: Add new clinical criteria document for Reblozyl (luspatercept). Coding Reviewed: Added: 96372 CPT, C9399, J3490, J3590, HCPCS, AND D56.1, D56.5 ICD-10-CM

References

1. Beta Thalassemia. National Organization for Rare Disorders. Available at <https://rarediseases.org/rare-diseases/thalassemia-major/>. 2019. Accessed on December 30, 2019.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: December 30, 2019.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
6. NCT02604433. ClinicalTrials.gov. U.S. National Library of Medicine. Available at <https://clinicaltrials.gov/ct2/show/NCT02604433?term=nct02604433&draw=2&rank=1>. Accessed on December 30, 2019.
7. Thalassemia. Cooley's Anemia Foundation. Available at <https://www.thalassemia.org/learn-about-thalassemia/about-thalassemia/>. 2019. Accessed on December 30, 2019.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association